Most RCC patients surveyed said telemedicine visits are comparable to in-person visits, but most oncology providers disagreed ...
Belzutifan has a “generally manageable” safety profile in patients with RCC, with a relatively low rate of treatment discontinuation.
Source: Getty Images Avelumab plus axitinib was associated with significantly longer progression-free survival than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback